Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials

Excerpt

Dacarbazine (DTIC) is currently the only agent approved throughout Europe for patients with previously untreated, advanced melanoma that is not restricted by tumour genotype (e.g. BRAF status). Based on recent trials in patients with previously untreated, advanced melanoma, median overall survival (OS) and a 1-year OS rate of approximately 9 months and 36% represent conservative, historical benchmarks for DTIC monotherapy [1–5]. Data from clinical trials and expanded access programmes show that ipilimumab treatment consistently provides a proportion of patients with long-term clinical benefit, irrespective of whether they are pretreated or treatment-naive. In Europe, ipilimumab is indicated for use in adult patients who have received prior therapy. To support the use of ipilimumab in the previously untreated setting, data were analysed from ipilimumab clinical trials. …